A Phase 2 interventional study of EPI-743 and Placebo in Noise-induced Hearing Loss, sponsored by Edison Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hearing Loss, Noise-Induced with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Noise-Induced · United States.
Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, this one is the 13th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 6th registered.
46 studies on the registry are indexed under Hearing Loss, Noise-Induced; 10 are open to participants now.
Browse Hearing Loss, Noise-Induced studies →6 of the 24 studies in Hearing Loss, Noise-Induced with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 45–65
Restorear Devices LLC · Sites in United States
Ages 18–55 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 2–6
San Diego State University · Sites in United States
Ages 18+ · Healthy volunteers
Truway Health, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Hearing Loss, Noise-Induced studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 1
First in 1999; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 88 across 30 interventional studies indexed under Hearing Loss, Noise-Induced.
Median enrollment 106 across the 22 interventional studies, 134,119 across the 2 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Edison Pharmaceuticals Inc, one of the names counted as PTC Therapeutics. Under that name alone:
Edison Pharmaceuticals Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.
PTC Therapeutics has 1 study filed under Hearing Loss, Noise-Induced — fewer than ten, so there is no comparison to draw.
1 of the studies in Hearing Loss, Noise-Induced with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06729632Restorear Devices LLCNon-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
If effective, administration of EPI-743 should have protective effects against temporary noise-induced hearing loss.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EPI-743 400 mg P.O. TID
Drug: EPI-743
Sesame Oil, NF in sealed gelatin capsules to match the test product
Drug: Placebo
EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
Also known as: VincerinoneTM, EPI743
2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
Also known as: Matching placebo
Pure tone audiometry
Time frame: 9 days
Time to recovery following acute noise exposure
Time frame: 9 days
Ran from Oct 2014 to primary completion in Nov 2015, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone